With an eye toward launching its first product, Mobilion Systems Inc. has revealed a $35 million series B funding round led by Amoon. Todd Sone, partner at Amoon who also is joining the company’s board, highlighted the duo’s common vision to develop technologies that offer high resolution and speed.
Life science companies doing business during a pandemic may believe that patients, judges and juries will look kindly on products that don’t perform as promised, but that may be an empty wish. Angela Seaton, an attorney with the D.C. office of Shook, Hardy & Bacon LLP, advised that companies that want to break into new markets because of pandemic-specific demand should do their homework, including a review of U.S. FDA warning letters.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Clearmask, Diazyme, Genosity, Illuminoss, Sensiva.
Keeping you up to date on recent developments in oncology, including: New and less expensive approach to digital PCR may improve cancer detection; Stromal cell subtypes identified in TNBC; Microbiome metabolites as immunotherapy adjuvants; Pandemic significantly impeded breast cancer follow-up.
LONDON – A pan-European consortium backed by 11 pharma companies is pooling resources in a €77.7 million (US$92.5 million) five-year plan to advance development of therapeutics for COVID-19 and other coronaviruses.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Astrazeneca, Emmaus, Immatics, Kimera, Krystal.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acepodia, Aligos, Arrowhead, Clovis, Deciphera, Follicum, GSK, Immatics, Immunicum, Immutep, Intravacc, Maxcyte, Novartis, Organicell, Poseida, Telix, The University of Texas MD Anderson Cancer Center, Ultimovacs, Vanda.
The COVID-19 pandemic has spurred a considerable amount of testing innovation, including more extensive use of saliva as a medium for detection of pathogens. The U.S. FDA has announced an emergency use authorization (EUA) to Yale School of Public Health for the Salivadirect testing protocol that requires no extraction of the SARS-CoV-2 virus’s RNA, a feature that Assistant Secretary for Health Brett Giroir said is “yet another testing innovation game changer that will reduce demand for scarce testing resources.”
RSS
